Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
Karthikeyan MurugesanDexter X JinLeah A CommentDavid FabrizioPriti S HegdeJulia A ElvinBrian AlexanderMia A LevyGarrett M FramptonMeagan MontesionSameek RoychowdhuryRazelle KurzrockJeffrey S RossLee A AlbackerRichard S P HuangPublished in: The oncologist (2022)
This work shows that CD274 copy number gains at varying thresholds predict different response to ICI blockade in non-squamous NSCLC. Considering these data, prospective clinical trials should further validate these findings, specifically in the context of PD-L1 IHC test results.
Keyphrases
- copy number
- mitochondrial dna
- clinical trial
- high grade
- genome wide
- low grade
- dna methylation
- small cell lung cancer
- nk cells
- electronic health record
- advanced non small cell lung cancer
- big data
- randomized controlled trial
- gene expression
- machine learning
- deep learning
- epidermal growth factor receptor
- tyrosine kinase